R
Relay Therapeutics, Inc. (RLAY)
9.60
0.00 (0.00%)
Get all premium features to the best stock analysis tool
9.60
0.00 (0.00%)
No Data
There are no news for this stock.
| NAME | RATIO | INDUSTRY | 5Y TREND | SCORE |
|---|---|---|---|---|
| Current ratio | 22.61 | 6.05 | 10 | |
| Quick ratio | 22.61 | 5.63 | 10 | |
| Debt to Equity | 0.06 | 0.30 | 9.0 | |
| Debt to Assets | 0.05 | 1.04 | 9.0 | |
| Interest coverage | N/A | -16.91 | 1.0 | |
| Weighted average score | 7.8 | |||
| METRIC | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Total Revenue | 1M | 26M | 10M | 15M | 15M |
| Gross Profit | -3M | 20M | 5M | 12M | 12M |
| Operating Income | -311M | -379M | -386M | -303M | -303M |
| Net Income | -291M | -342M | -338M | -276M | -276M |
| EBITDA | -307M | -374M | -380M | -299M | -299M |
| NAME | REVENUE GROWTH | EPS GROWTH | SCORE |
|---|---|---|---|
| Current quarter | -37.12 | 20.98 | 5.5 |
| Next quarter | -87.76 | 7.05 | 3.0 |
| Current year | -57.74 | 4.58 | 2.5 |
| Next year | 237.96 | 3.78 | 7.0 |
| Weighted average score | 4.5 | ||
| NAME | REVENUE | NET INCOME | EPS | FCF | SCORE |
|---|---|---|---|---|---|
| Q/Q | 999 | 25.97 | 25.58 | 27.77 | 10 |
| Y/Y | 999 | 27.78 | 28.89 | 22.47 | 10 |
| 3y average | 580.81 | 0.56 | 13.16 | -1.33 | 5.3 |
| 5y average | 318.34 | -114.47 | 20.19 | -36.97 | 5.5 |
| Weighted average score | 7.7 | ||||
| NAME | CURRENT | INDUSTRY | SCORE |
|---|---|---|---|
| Dividend yield | 0.00 | N/A | 1.0 |
| Payout ratio | 0.00 | N/A | 1.0 |
| 5-year dividend growth rate | N/A | N/A | 1.0 |
| Years of dividend increase | N/A | N/A | 1.0 |
| Weighted average score | 1.0 | ||
| NAME | SCALE | SCORE |
|---|---|---|
| Market share | None | 1.0 |
| Intangible assets | None | 1.0 |
| Switching costs | None | 1.0 |
| Network effect | None | 1.0 |
| Economies of scale | None | 1.0 |
| Weighted average score | 1.0 | |
Company's cash reserves $84.0M significantly exceed its total debt $32.5M, ensuring strong financial flexibility
Total current assets $578.3M exceed Total current liabilities $25.6M, highlighting excellent liquidity
Debt-to-equity ratio (0.1) is well below the industry average (0.3), showcasing prudent financial management
Interest expense exists but EBIT data is unavailable, indicating potential profitability concerns
Negative free cash flow -$44.9M limits the company's ability to reinvest or pay down debt